Naminidil
Naminidil is an ATP-sensitive potassium channel opener with vasodilator activity which was under development as a topical medication for the treatment of androgenic alopecia but was never marketed. The drug was under development by Bristol-Myers Squibb and reached phase 2 clinical trials by 2001. One of the phase 2 trials compared naminidil, minoxidil, and placebo for alopecia. However, no results of the study appear to have been made available. Development of naminidil was discontinued by 2008. In terms of chemical structure, naminidil is a guanidine derivative and is structurally distinct from minoxidil.